- INVESTMENT OPPORTUNITIES
- SECONDARY MARKET
The scientific team has extensive experience in melatonin for more than 30 years, backed by numerous international publications. The management team has put the company at the forefront of the market.
Pharmamel shows in its Phase II results a 20% reduction in hospitalization in patients with sepsis, which would substantially reduce cost. This cost reduction in a growing market could propel the company to success.
I am really interested and I am sure, due to my own experience with melatonin, that this project would be a success in the medical field.
This is the final investment you will make. The amount you have entered has probably been rounded to match the share price.